Related Experiment Video
Updated: Dec 4, 2025
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
Immunomagnetic Reduction Detects Plasma Aβ1-42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline
Shieh-Yueh Yang1,2, Huei-Chun Liu3, Wen-Ping Chen4
1MagQu Co., Ltd., New Taipei City, 231, Taiwan. syyang@magqu.com.
Abstract:
Although the concentrations of Alzheimer's disease (AD) biomarkers Aβ1-40, Aβ1-42 and tau protein are very low in human plasma, ultrasensitive assays such as immunomagnetic reduction (IMR) are able to precisely quantify them. Review articles have described the detailed working mechanism of IMR and revealed the feasibility of detecting early-stage AD by assaying these plasma biomarkers with IMR. In this review, we aimed to compare the significance of these plasma biomarkers in predicting cognitive decline in patients with Down syndrome, stroke, or amnestic mild cognitive impairment based on findings in the literature. We found that plasma Aβ1-42 might play the predominant role in predicting cognitive decline in these patients.
Insights
Ultrasensitive assays can measure Alzheimer's disease (AD) biomarkers in plasma. Plasma amyloid-beta 42 (Aβ1-42) shows the most promise for predicting cognitive decline in patients with Down syndrome, stroke, or mild cognitive impairment.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Diagnostics
Background:
- Alzheimer's disease (AD) biomarkers like Aβ1-40, Aβ1-42, and tau are present at very low concentrations in human plasma.
- Ultrasensitive assays, such as immunomagnetic reduction (IMR), enable precise quantification of these low-concentration biomarkers.
Purpose of the Study:
- To review and compare the significance of plasma biomarkers (Aβ1-40, Aβ1-42, tau) in predicting cognitive decline.
- To focus on patient cohorts including Down syndrome, stroke, and amnestic mild cognitive impairment (MCI).
Main Methods:
- Literature review of studies utilizing ultrasensitive assays, specifically IMR.
- Analysis of findings related to plasma biomarker concentrations and their correlation with cognitive decline in specific patient groups.
Main Results:
- Review articles confirm the feasibility of detecting early-stage AD using plasma biomarkers with IMR.
- Plasma Aβ1-42 emerged as a potentially predominant biomarker for predicting cognitive decline across the studied patient groups.
Conclusions:
- Plasma Aβ1-42 holds significant potential as a predictive biomarker for cognitive decline in diverse neurological conditions.
- Ultrasensitive assays like IMR are crucial for advancing the detection and monitoring of neurodegenerative diseases through plasma biomarkers.
